Cutaneous Side Effects of Immunosuppressive Drugs Other Than Neoplasms

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
bookPart
Data de publicação
2022
DOI
Scopus
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER INTERNATIONAL PUBLISHING
Autores
Citação
Miotto, I. Z.; de Oliveira, W. R. P.. Cutaneous Side Effects of Immunosuppressive Drugs Other Than Neoplasms. In: . Atlas of Dermatologic Diseases in Solid Organ Transplant Recipients: SPRINGER INTERNATIONAL PUBLISHING, 2022. p.47-67.
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Solid organ transplant recipients are susceptible to various dermatological side effects as a consequence of long-term immunosuppressive therapy. Malignancies and infections are well-studied complications, but there is less information regarding other nonmalignant skin changes, such as inflammatory manifestations. The aim of this chapter is to describe the cutaneous side effects related to the following drugs: Systemic steroids, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, mTOR inhibitors (sirolimus and everolimus), and newer agents, such as monoclonal antibodies and biologic drugs. Transplant care providers must be able to recognize and properly manage these cutaneous findings in order to limit associated morbidity and mortality. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.
Palavras-chave
Acneiform eruption, Azathioprine, Cyclosporine, Everolimus, Hypertrichosis, Immunosuppression, Mycophenolate mofetil, Prednisone, Sirolimus, Tacrolimus
URI
https://observatorio.fm.usp.br/handle/OPI/57258
Referências
  1. Ilyas M., Colegio O.R., Kaplan B., Cutaneous toxicities from transplantation-related medications, Am J Transplant, 17, pp. 2782-2789, (2017)
  2. Miotto I.Z., Souza B.D.C.E., Tyring S.K., de Oliveira W.R.P., Immunosuppressant-induced cutaneous drug reactions in solid organ transplant recipients, Transpl Immunol, 64, (2021)
  3. Allison T.L., Immunosuppressive therapy in transplantation, Nurs Clin North Am, 51, 1, pp. 107-120, (2016)
  4. Kazandjieva J., Tsankov N., Drug-induced acne, Clin Dermatol, 35, 2, pp. 156-162, (2017)
  5. Fardet L., Flahault A., Kettaneh A., Tiev K.P., Genereau T., Toledano C., Et al., Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient’s opinion, Br J Dermatol, 157, 1, pp. 142-148, (2007)
  6. Dessinioti C., Antoniou C., Katsambas A., Acneiform eruptions, Clin Dermatol, 32, 1, pp. 24-34, (2014)
  7. Kee M., Pathology of the Skin, 51, pp. 348-353, (1999)
  8. Bidinger J.J., Sky K., Battafarano D.F., Henning J.S., The cutaneous and systemic manifestations of azathioprine hypersensitivity syndrome, J am Acad Dermatol, 65, 1, pp. 184-191, (2011)
  9. Patel A.A., Swerlick R.A., McCall C.O., Azathioprine in dermatology: The past, the present, and the future, J am Acad Dermatol, 55, 3, pp. 369-389, (2006)
  10. Calbo Mayo J.M., Blasco Colmenarejo M., Rivera Vaquerizo P.J., Vicente Gutierrez M., Hypersensitivity reaction to azathioprine in a patient with ulcerative colitis, Inflamm Bowel Dis, 10, 5, (2004)
  11. Yiasemides E., Thom G., Azathioprine hypersensitivity presenting as a neutrophilic dermatosis in a man with ulcerative colitis, Australas J Dermatol, 50, 1, pp. 48-51, (2009)
  12. Frank J., Fett N., Azathioprine hypersensitivity syndrome, J Rheumatol, 44, 12, pp. 1876-1877, (2017)
  13. Choonhakarn C., Chaowattanapanit S., Azathioprine-induced Sweet’s syndrome and published work review, J Dermatol, 40, 4, pp. 267-271, (2013)
  14. Weng R.R., Foster C.E., Hsieh L.L., Patel P.R., Oral ulcers associated with mycophenolate mofetil use in a renal transplant recipient, Am J Health Syst Pharm, 68, 7, pp. 585-588, (2011)
  15. van Gelder T., Ter Meulen C.G., Hene R., Weimar W., Hoitsma A., Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil, Transplantation, 75, 6, pp. 788-791, (2003)
  16. McDonald S.K., Goh M.S., Chong A.H., Successful treatment of cyclosporine-induced sebaceous hyperplasia with oral isotretinoin in two renal transplant recipients, Australas J Dermatol, 52, 3, pp. 227-230, (2011)
  17. Oliveira W.R.P., Tirico M.C.C.P., Souza A.A.V., Codarin F.R., Silva L.L.C., Festa N.C., Skin lesions in organ transplant recipients: A study of 177 consecutive Brazilian patients, Int J Dermatol, 58, 4, pp. 440-448, (2019)
  18. Heaphy M.R., Shamma H.N., Hickmann M., Cyclosporine-induced folliculodystrophy, J am Acad Dermatol, 50, pp. 310-315, (2004)
  19. Salim A., Reece S.M., Smith A.G., Harrison D., Ramsay H.M., Harden P.N., Et al., Sebaceous hyperplasia and skin cancer in patients undergoing renal transplant, J am Acad Dermatol, 55, 5, pp. 878-881, (2006)
  20. Tokgoz B., Sari H.I., Yildiz O., Aslan S., Sipahioglu M., Okten T., Et al., Effects of azithromycin on cyclosporine-induced gingival hyperplasia in renal transplant patients, Transplant Proc, 36, 9, pp. 2699-2702, (2004)
  21. Dromer C., Doutre M., Beylot C., Cyclosporine-induced follicular eruption, Ann Dermatol Vénéréol, 135, pp. 58-62, (2008)
  22. Shapiro R., Fung J.J., Jain A.B., Parks P., Todo S., Starzl T.E., The side effects of FK 506 in humans, Transplant Proc, 22, 1, pp. 35-36, (1990)
  23. Tricot L., Lebbe C., Pillebout E., Martinez F., Legendre C., Thervet E., Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients, Transplantation, 80, 11, pp. 1546-1549, (2005)
  24. Iorizzo M., Tosti A., Treatments options for alopecia, Expert Opin Pharmacother, 16, 15, pp. 2343-2354, (2015)
  25. Klawitter J., Nashan B., Christians U., Everolimus and sirolimus in transplantation-related but different, Expert Opin Drug Saf, 14, 7, pp. 1055-1070, (2015)
  26. Campistol J.M., de Fijter J.W., Flechner S.M., Langone A., Morelon E., Stockfleth E., MTOR inhibitor-associated dermatologic and mucosal problems, Clin Transpl, 24, 2, pp. 149-156, (2010)
  27. Mahe E., Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy 1, Transplantation, 79, 4, pp. 476-482, (2005)
  28. Mahe E., Morelon E., Lechaton S., Drappier J.C., de Prost Y., Kreis H., Et al., Acne in recipients of renal transplantation treated with sirolimus: Clinical, microbiologic, histologic, therapeutic, and pathogenic aspects, J am Acad Dermatol, 55, 1, pp. 139-142, (2006)
  29. Kunzle N., Venetz J., Pascual M., Panizzon R.G., Laffi E., Sirolimus-induced acneiform eruption, Dermatology, 211, pp. 366-369, (2005)
  30. Montalbano M., Neff G.W., Yamashiki N., Meyer D., Bettiol M., Slapak-Green G., Et al., A retrospective review of liver transplant patients treated with sirolimus from a single center: An analysis of sirolimus-related complications, Transplantation, 78, 2, pp. 264-268, (2004)
  31. Valente J.F., Hricik D., Weigel K., Seaman D., Knauss T., Siegel C.T., Et al., Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation, Am J Transplant, 3, 9, pp. 1128-1134, (2003)
  32. Sonis S., Treister N., Chawla S., Demetri G., Haluska F., Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients, Cancer, 116, 1, pp. 210-215, (2010)
  33. Dioguardi M., Troiano G., Lo Russo L., Giannatempo G., Rubini C., Bertossi D., Et al., Occult co-infection in the oral cavity with cytomegalovirus during immunosuppression, J Transl Sci, 1, 2, pp. 26-30, (2015)
  34. Pasin V.P., Pereira A.R., de Carvalho K.A., de Paiva J.M.G., Enokihara M.M.S.S., Porro A.M., New drugs, new challenges for dermatologists: Mucocutaneous ulcers secondary to everolimus, An Bras Dermatol, 90, 3, pp. S165-S167, (2015)
  35. Totonchy M.B., Colegio O.R., Christensen S.R., Sirolimus-associated rapid progression of leg ulcers in a renal transplant recipient, JAMA Dermatol, 153, 1, pp. 105-106, (2017)
  36. Liu L.S., McNiff J.M., Colegio O.R., Palmoplantar peeling secondary to sirolimus therapy, Am J Transplant, 14, 1, pp. 221-225, (2014)
  37. Moro J.A., Almenar L., Martinez-Dolz L., Sanchez-Lazaro I., Aguero J., Salvador A., Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation, Transplant Proc, 40, 9, pp. 3034-3036, (2008)
  38. de Ataide E.C., Perales S.R., Bortoto J.B., Peres M.A.O., Filho F.C., Stucchi R.S.B., Et al., Immunomodulation, acute renal failure, and complications of basiliximab use after liver transplantation: Analysis of 114 patients and literature review, Transplant Proc, 49, 4, pp. 852-857, (2017)
  39. Martin S.T., Tichy E.M., Gabardi S., Belatacept: A novel biologic for maintenance immunosuppression after renal transplantation, Pharmacotherapy, 31, 4, pp. 394-407, (2011)
  40. Grinyo J., Charpentier B., Pestana J.M., Vanrenterghem Y., Vincenti F., Reyes-Acevedo R., Et al., An integrated safety profile analysis of belatacept in kidney transplant recipients, Transplantation, 90, 12, pp. 1521-1527, (2010)

Coleções
Livros e Capítulos de Livros - HC/ICHC